秒速时时彩

You are here: Home> Investor Relations> Announcement
  • 31

    2019-12

    The Group's Pregabalin Capsules Approved for New American Simple Drugs

    CSPC's Pregabalin Capsules Approved for New American Simple Drugs ...

  • 31

    2019-12

    Voluntary Announcement-Termination of Product Cooperative Development and Strategic Cooperation Agreement

    Voluntary announcement to terminate product cooperation development and strategic cooperation agreement ...

  • 20

    2019-12

    CSPC's L-Amlodipine maleate is approved by the FDA

    CSPC's L-Amlodipine maleate was approved by the US FDA for new drug marketing ...

  • 11

    2019-12

    CSPC `` ibuprofen tablets '' pass consistency evaluation

  • 02

    2019-12

    Monthly Return Monthly Return of Equity Issuer on Movements in Securities for the Month Ended November 30, 2019

  • 02

    2019-12

    [Continuing Connected Transaction] Amendment of Annual Caps for Existing Continuing Connected Transactions

  • 27

    2019-11

    CSPC submits clinical trial application for the first innovative drug of its kind in Australia, ALMB-0168, in Australia

  • 27

    2019-11

    Shiyao Group cefixime capsules passed the consistency evaluation

  • 08

    2019-11

    [Other-Business Development Update] Voluntary Announcement-Product Transfer Agreement

  • 06

    2019-11

    [Date of Board Meeting] Date of Board Meeting

  • 01

    2019-11

    Monthly Return Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2019

  • 01

    2019-11

    Clinic Group's "Clindamycin Hydrochloride Capsule" Passes Consistency Evaluation

  • 01

    2019-11

    CSPC's cephalosporin capsules passed consistency evaluation

  • 01

    2019-11

    CSPC `` Enalapril Maleate '' Passes Consistency Evaluation

  • 01

    2019-11

    CSPC Group's Recombinant Anti-EpCAM and CD3 Human-Mouse Chimeric Bispecific Antibodies for Injection Received US FDA Clinical Trial Approval